<SEC-DOCUMENT>0001193125-21-180325.txt : 20210603
<SEC-HEADER>0001193125-21-180325.hdr.sgml : 20210603
<ACCEPTANCE-DATETIME>20210602203429
ACCESSION NUMBER:		0001193125-21-180325
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210602
FILED AS OF DATE:		20210603
DATE AS OF CHANGE:		20210602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		21990924

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d187119d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated June 2, 2021 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d187119dex991.htm">IMMUTEP SECURES SECOND EUROPEAN PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE LAG-3 PROTEIN, IN COMBINATION WITH A PD-1 PATHWAY INHIBITOR </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: June 2, 2021 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d187119dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="tx187119_1"></A>Exhibit 99.1 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g187119g24q71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX/Media Release </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP SECURES SECOND EUROPEAN PATENT FOR EFTILAGIMOD ALPHA, A SOLUBLE <FONT STYLE="white-space:nowrap">LAG-3</FONT> PROTEIN, IN
COMBINATION WITH A <FONT STYLE="white-space:nowrap">PD-1</FONT> PATHWAY INHIBITOR </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; </B><B>2</B><B></B><B>&nbsp;June 2021
&#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#147; or &#147;the Company&#147;), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of
patent number<B> </B>EP3473263 entitled &#147;Combined Preparations for the Treatment of Cancer&#148; by the European Patent Office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This European patent
was filed as a divisional application and follows the grant of the European parent patent announced in November 2018, and the corresponding United States patents announced in December 2020 and March 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The claims of the new European divisional patent build on the protection provided by the parent patent and protect Immutep&#146;s intellectual property
relating to combined therapeutic preparations comprising (a)&nbsp;lead active immunotherapy candidate eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), which is a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT
STYLE="white-space:nowrap">(LAG-3Ig),</FONT> and (b)&nbsp;a <FONT STYLE="white-space:nowrap">PD-1</FONT> or <FONT STYLE="white-space:nowrap">PD-L1</FONT> inhibitor. The claims are also directed to related methods of use in the treatment of cancer.
The patent expiry date is 8&nbsp;January 2036. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Again, this new divisional patent in Europe is very important as it specifically covers the
combination of active ingredients being evaluated in many of our clinical trials, including those being reported at the upcoming ASCO 2021 Annual Meeting. It also highlights the critical investments we are making to protect efti which underpin
further clinical development and commercialisation of this asset. Building a robust patent estate is a priority for our business and a key part of the process of bringing innovative medicines to the market to ultimately improve patient
outcomes,&#148; said Marc Voigt, CEO of Immutep. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology company that is a leader in the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related
immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product candidate is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble
<FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC)
activator being explored in cancer and infectious disease. Immutep is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761) for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> products,
including antibodies for immune response modulation, are being developed by Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be
found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 12, 95 Pitt Street, Sydney NSW
2000 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g187119g24q71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>cstrong@citadelmagnus.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim
McCarthy, LifeSci Advisors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (212) 915.2564;&nbsp;<U>tim@lifesciadvisors.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Board of Immutep Limited. </P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level 12, 95 Pitt Street, Sydney NSW 2000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g187119g24q71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g187119g24q71.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M# P,# P,# P,#/_  !$( (8#( ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3G#>8_RGW%?J?\/HGMO FD12_P"MCM(E?G/.T4!N:R0\<\TI3Y>M.4?W?UI
M?6@.MQXZ4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ)937=E<1W%O!*87D4<!QU!K+\%?''PW\1M:NM/TF\:ZN+,$RKY+H%P<<$@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3)O#GPYT.QNU\NZL[.*WE0'[KA0"*Z#8.G?'IS0L?)^51W% $E%%% !1110
M4444 %%%% !1111< HHZ49HN 449HZT7 ****+@%%&:,T7 **,T9HN 449HS
M1< HHS1FBX!11FC-%P"BC-&:+@%%&:,T7 **,T9HN 449HS1< HHS1FBX!11
MFCK1< HHHHN 449HS1< HHS1FBX!11FC-%P"BC-&:+@%%&:,T7 **,T9HN 4
M49HS1< HHS1FBX!11FC-%P"BC-&:+@%%&:.M%P"BBBBX!1111< HHZ49HN 4
M49HS1< HHS1FBX!11FC-%P"BC-&:+@%%&:,T7 **,T9HN 449HS1< HHS1FB
MX!11FCK1< HHHHN 44447 **.E&:+@%%&:,T7 **,T9HN 449HS1< HHS1FB
MX!11FC-%P"BC-&:+@%%&:,T7 **,T4 >$?\ #QOX5_\ 0>N/_ "?_P")H_X>
M-_"O_H/7'_@!/_\ $UXR/^"6%^?^8]'^?_V-*/\ @EA>@?-KR?G_ /8UY'ML
M;_(CX_ZUGG_/N)[*?^"C/PK(_P"0]<?^ $__ ,32?\/%_A7_ -!ZX_\  "?_
M .(KQL_\$L;W_H/1_G_]C2_\.L+[_H/1_G_]C1[;&_R(/K>>?\^T>Q_\/%_A
M7_T'KC_P G_^(I1_P49^%:_\QZX_\ )__B:\;_X=87W_ $'H_P __L:3_AUA
M>CKKT?Y__8T>VQO\B#ZWGG_/M'LO_#QOX5_]!ZX_\ )__B:/^'C?PK_Z#UQ_
MX 3_ /Q->-_\.L;S_H/)^?\ ]C1_PZQO/^@\GY__ &-+VV-_D#ZUGG_/N)['
M_P /%_A7_P!!ZX_\ )__ (BC_AXO\*_^@]<?^ $__P 17C@_X)87W_0>C_/_
M .QH_P"'6%]_T'H_S_\ L:?ML;_(@^MY[_S[1['_ ,/%_A7_ -!ZX_\  "?_
M .(H_P"'B_PK_P"@]<?^ $__ ,17CG_#K"^_Z#T?Y_\ V-'_  ZPOO\ H/1_
MG_\ 8T>VQO\ (@^MY[_S[1['_P /%_A7_P!!ZX_\ )__ (BC_AXO\*_^@]<?
M^ $__P 17CG_  ZPOO\ H/1_G_\ 8T?\.L+[_H/1_G_]C1[;&_R(/K>>_P#/
MM'L?_#Q?X5_]!ZX_\ )__B*/^'B_PK_Z#UQ_X 3_ /Q%>.?\.L+[_H/1_G_]
MC1_PZPOO^@]'^?\ ]C1[;&_R(/K>>_\ /M'L?_#Q?X5_]!ZX_P# "?\ ^(H_
MX>+_  K_ .@]<?\ @!/_ /$5XY_PZPOO^@]'^?\ ]C1_PZPOO^@]'^?_ -C1
M[;&_R(/K>>_\^T>Q_P##Q?X5_P#0>N/_   G_P#B*/\ AXO\*_\ H/7'_@!/
M_P#$5XY_PZPOO^@]'^?_ -C1_P .L+[_ *#T?Y__ &-'ML;_ "(/K>>_\^T>
MQ_\ #Q?X5_\ 0>N/_ "?_P"(H_X>+_"O_H/7'_@!/_\ $5XY_P .L+[_ *#T
M?Y__ &-'_#K"^_Z#T?Y__8T>VQO\B#ZWGO\ S[1['_P\7^%?_0>N/_ "?_XB
MC_AXO\*_^@]<?^ $_P#\17CG_#K"^_Z#T?Y__8T?\.L+[_H/1_G_ /8T>VQO
M\B#ZWGO_ #[1['_P\7^%?_0>N/\ P G_ /B*/^'B_P *_P#H/7'_ ( 3_P#Q
M%>.?\.L+[_H/1_G_ /8T?\.L+[_H/1_G_P#8T>VQO\B#ZWGO_/M'L?\ P\7^
M%?\ T'KC_P  )_\ XBC_ (>+_"O_ *#UQ_X 3_\ Q%>.?\.L+[_H/1_G_P#8
MT?\ #K"^_P"@]'^?_P!C1[;&_P B#ZWGO_/M'L?_  \7^%?_ $'KC_P G_\
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M\ )__B*/^'B_PK_Z#UQ_X 3_ /Q%>.?\.L+[_H/1_G_]C1_PZPOO^@]'^?\
M]C1[;&_R(/K>>_\ /M'L?_#Q?X5_]!ZX_P# "?\ ^(H_X>+_  K_ .@]<?\
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M /8T?\.L+[_H/1_G_P#8T>VQO\B#ZWGO_/M'L?\ P\7^%?\ T'KC_P  )_\
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M[1['_P /%_A7_P!!ZX_\ )__ (BC_AXO\*_^@]<?^ $__P 17CG_  ZPOO\
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M /8T?\.L+[_H/1_G_P#8T>VQO\B#ZWGO_/M'L?\ P\7^%?\ T'KC_P  )_\
MXBE'_!1GX5K_ ,QZX_\  "?_ .)KQO\ X=87W_0>C_/_ .QIK?\ !+"^S_R'
MH_S_ /L:/;8W^1!];SW_ )]H]F_X>-_"O_H/7'_@!/\ _$T?\/&_A7_T'KC_
M , )_P#XFO&E_P""6-]GG7H_S_\ L:7_ (=8WG_0>3\__L:/;8W^0/K6>?\
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M]IOSHHH /LG^TWYT?9/]IJ** #['_M-1]C_VFHHH /LG^TWYT?9/]IOSHHH
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MVF_.BB@ ^R?[3?G1]D_VF_.BB@ ^R?[3?G1]D_VFHHH /L?^TU'V/_::BB@
M^Q_[34?8_P#::BB@ ^R?[34?9/\ :;\Z** #[)_M-^='V3_:;\Z** #[)_M-
M^='V3_:;\Z** #[)_M-^='V3_:;\Z** #[)_M-^='V3_ &F_.BB@ ^R?[3?G
M1]D_VF_.BB@ ^R?[3?G1]D_VF_.BB@ ^R?[3?G1]D_VF_.BB@ ^R?[34?9/]
'MJ** L?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
